Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Overview

NASDAQ:GPCR - US86366E1064 - ADR

22.08 USD
+2.32 (+11.74%)
Last: 9/5/2025, 8:18:53 PM
21.99 USD
-0.09 (-0.41%)
After Hours: 9/5/2025, 8:18:53 PM

GPCR Key Statistics, Chart & Performance

Key Statistics
52 Week High45.37
52 Week Low13.22
Market Cap1.27B
Shares57.60M
Float18.15M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.18
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11/bmo
IPO02-03 2023-02-03
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


GPCR short term performance overview.The bars show the price performance of GPCR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

GPCR long term performance overview.The bars show the price performance of GPCR in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of GPCR is 22.08 USD. In the past month the price increased by 36.3%. In the past year, price decreased by -40.24%.

STRUCTURE THERAPEUTICS INC / GPCR Daily stock chart

GPCR Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.03 688.28B
JNJ JOHNSON & JOHNSON 17.84 429.72B
AZN ASTRAZENECA PLC-SPONS ADR 18.4 253.31B
NVS NOVARTIS AG-SPONSORED ADR 14.66 251.14B
NVO NOVO-NORDISK A/S-SPONS ADR 14.13 245.41B
MRK MERCK & CO. INC. 11 211.59B
PFE PFIZER INC 7.34 141.46B
SNY SANOFI-ADR 10.47 113.41B
BMY BRISTOL-MYERS SQUIBB CO 7 95.95B
GSK GSK PLC-SPON ADR 8.96 81.59B
ZTS ZOETIS INC 24.65 67.95B
TAK TAKEDA PHARMACEUTIC-SP ADR 53.1 48.64B

About GPCR

Company Profile

GPCR logo image Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 199 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Company Info

STRUCTURE THERAPEUTICS INC

611 Gateway Blvd Suite 223

South San Francisco CALIFORNIA US

Employees: 199

GPCR Company Website

GPCR Investor Relations

Phone: 16282299277

STRUCTURE THERAPEUTICS INC / GPCR FAQ

What is the stock price of STRUCTURE THERAPEUTICS INC today?

The current stock price of GPCR is 22.08 USD. The price increased by 11.74% in the last trading session.


What is the ticker symbol for STRUCTURE THERAPEUTICS INC stock?

The exchange symbol of STRUCTURE THERAPEUTICS INC is GPCR and it is listed on the Nasdaq exchange.


On which exchange is GPCR stock listed?

GPCR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for STRUCTURE THERAPEUTICS INC stock?

20 analysts have analysed GPCR and the average price target is 77.68 USD. This implies a price increase of 251.8% is expected in the next year compared to the current price of 22.08. Check the STRUCTURE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is STRUCTURE THERAPEUTICS INC worth?

STRUCTURE THERAPEUTICS INC (GPCR) has a market capitalization of 1.27B USD. This makes GPCR a Small Cap stock.


How many employees does STRUCTURE THERAPEUTICS INC have?

STRUCTURE THERAPEUTICS INC (GPCR) currently has 199 employees.


What are the support and resistance levels for STRUCTURE THERAPEUTICS INC (GPCR) stock?

STRUCTURE THERAPEUTICS INC (GPCR) has a support level at 19.3 and a resistance level at 23.1. Check the full technical report for a detailed analysis of GPCR support and resistance levels.


Should I buy STRUCTURE THERAPEUTICS INC (GPCR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does STRUCTURE THERAPEUTICS INC (GPCR) stock pay dividends?

GPCR does not pay a dividend.


When does STRUCTURE THERAPEUTICS INC (GPCR) report earnings?

STRUCTURE THERAPEUTICS INC (GPCR) will report earnings on 2025-11-11, before the market open.


What is the Price/Earnings (PE) ratio of STRUCTURE THERAPEUTICS INC (GPCR)?

STRUCTURE THERAPEUTICS INC (GPCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.18).


What is the Short Interest ratio of STRUCTURE THERAPEUTICS INC (GPCR) stock?

The outstanding short interest for STRUCTURE THERAPEUTICS INC (GPCR) is 39.98% of its float. Check the ownership tab for more information on the GPCR short interest.


GPCR Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is a bad performer in the overall market: 88.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GPCR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GPCR. GPCR has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GPCR Financial Highlights

Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS decreased by -92.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -21.92%
ROE -23.18%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-500%
Sales Q2Q%N/A
EPS 1Y (TTM)-92.73%
Revenue 1Y (TTM)N/A

GPCR Forecast & Estimates

20 analysts have analysed GPCR and the average price target is 77.68 USD. This implies a price increase of 251.8% is expected in the next year compared to the current price of 22.08.


Analysts
Analysts87
Price Target77.68 (251.81%)
EPS Next Y15.2%
Revenue Next YearN/A

GPCR Ownership

Ownership
Inst Owners99.97%
Ins Owners3.08%
Short Float %39.98%
Short Ratio9.26